Bicara Therapeutics (BCAX) Cash & Equivalents (2023 - 2026)

Bicara Therapeutics (BCAX) has 4 years of Cash & Equivalents data on file, last reported at $323.5 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 30.0% year-over-year to $323.5 million; the trailing twelve-month figure through Mar 2026 stood at $323.5 million (down 30.0% YoY), and the FY2025 full-year result was $96.7 million, down 80.26% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $323.5 million, up from $96.7 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $520.8 million in Q3 2024 and bottomed at $96.7 million in Q4 2025.
• The 4-year median for Cash & Equivalents is $380.0 million (2025), against an average of $341.4 million.
• The widest annual swing landed in 2024, when Cash & Equivalents soared 112.51%; it then tumbled 80.26% in 2025.
• A 4-year view of Cash & Equivalents shows it stood at $230.4 million in 2023, then soared by 112.51% to $489.7 million in 2024, then sank by 80.26% to $96.7 million in 2025, then surged by 234.55% to $323.5 million in 2026.
• The last three Cash & Equivalents figures came in at $323.5 million (Q1 2026), $96.7 million (Q4 2025), and $171.7 million (Q3 2025), per Business Quant data.

Peer Comparison